CytoSorbents Corporation NASDAQ CM: CTSO An Emerging Leader in Critical Care Immunotherapy Year 2014 Earnings Call March 31, 2015





Safe Harbor Statement

Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents, Inc (now known as CytoSorbents Medical Inc) and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. It is routine for our internal projections and expectations to change. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the projections or forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forwardlooking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies' products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forwardlooking statements. Readers are referred to a discussion of important risk factors detailed in the Company's Form 10-K filed with the Securities and Exchange Commission on March 31, 2015 and other reports and documents filed from time to time by us, which are available online at www.sec.gov.



CytoSorbents is Well-Positioned as A Leader in Critical Care Immunotherapy



Leading the Prevention or Treatment of Life-Threatening Inflammation in the ICU and Cardiac Surgery using CytoSorb[®] Blood Purification



2014: A Strong Year of Growth



Achieved 2014 CytoSorb Sales of \$3.1M

Driven by a growing combination of Direct Sales, Independent Distributor Sales, and Strategic Partner Sales





2nd CytoSorb Germany User's Meeting





1st International CytoSorb User's Meeting





ISICEM 2015





More Published Case Reports & Studies



Launched International CytoSorb Registry

• The home of 40+ planned investigator initiated studies with many already enrolling





Launched New CytoSorb Website





www.cytosorb.com

Partnered with Global Leaders



Expansion of Biocon Partnership

- According to Biocon, hundreds of patients have benefited from CytoSorb[®] therapy and orders continue to increase
- Expanded agreement beyond sepsis to all critical care applications and cardiac surgery with a focus on the systemic inflammatory response syndrome (SIRS) in India and select emerging countries
- Negotiated a co-development agreement where Biocon has committed to conduct and publish results from multiple Investigator Initiated studies and patient case studies
- Biocon will continue to market CytoSorb[®] with their critical care antibiotics as the "most comprehensive treatment" of sepsis
- Biocon has also agreed to an increase in annual minimum sales targets which should result in significantly increased sales over the life of the agreement







Fresenius Medical Care

- Entered into a 6 country partnership with Fresenius, the largest dialysis company in the world for exclusive distribution of CytoSorb® in critical care in France, Sweden, Norway, Finland, Denmark and Poland
- Leveraging Fresenius' #1 or #2 position in critical care in these territories and elsewhere in the world
- CytoSorb® is a key part of Fresenius' growth strategy in critical care
- Strong sales force and distribution
- CytoSorb has been used on the Fresenius multiFiltrate thousands of times
- Potential for much broader synergy and expansion in the future







14

Cardiac Surgery Initial Partnership

- Entered into an initial partnership with a top-four global medical device company in cardiac surgery to use CytoSorb[®] intra-operatively during cardiac surgery in France
- Initial evaluation phase expected to be complete in Q2 2015
- Following a successful evaluation, the two parties plan to jointly determine how to potentially expand upon both the size and geographic footprint of its partnership



- France is the second largest medical device market and one of the highest volume cardiac surgery markets in the EU
- Medtronic, Sorin, Maquet and Terumo are top firms in the cardiac surgery space worldwide



Focus on Generating Clinical Data




FDA Approval of IDE for REFRESH Study

- **REFRESH** (<u>R</u>eduction in <u>FRE</u>e <u>H</u>emoglobin) Trial is a 20-patient multi-center feasibility study evaluating the safety of CytoSorb use intra-operatively in a bypass circuit in a heart-lung machine during complex cardiac surgery as a means of reducing plasma-free hemoglobin and other inflammatory mediators that can cause post-operative complications
- Expected to be completed this year, beginning the clinical trial process to seek US FDA approval for CytoSorb










Infrastructure to Drive Clinical Data



18

Increased Investor Awareness





NASDAQ Capital Market Listed

CytoSorbents (CTSO) Up-listed to NASDAQ in December 2014

• Average daily trading volume: 200K shares (\$3M daily trading value) vs 30,000 prior to up-listing







#11 on Forbes Best Performing Stocks of 2014

CytoSorbents Achieved Strong Stock Performance in 2014 comparing favorably to peers

Ticker	Company	Total return in 2014 (%)	Market capitalization (\$MIL)	Quarterly sales (\$MIL)
AVNR Avanir F	Pharmaceuticals, Inc. Class A	404.5	3,284.5	32.7
OVAS OvaScie	ence, Inc.	383.8	1,075.3	0.0
AGIO Agios P	harmaceuticals, Inc.	367.8	4,103.9	33.9
BLUE Bluebird	l Bio, Inc.	337.2	2,875.6	6.4
RCPT Recepto	os, Inc.	322.6	3,792.8	3.5
TGTX TG The	rapeutics, Inc.	306.2	696.4	0.0
RNA Prosens	a Holding NV	301.5	677.0	0.0
PTX Pernix T	herapeutics Holdings PTX +2.23%,	272.6	359.6	31.5
Inc.				
ACHN Achillion	Pharmaceuticals ACHN -8.13%, Inc.	269.1	1,228.0	0.0
FOLD Amicus	Therapeutics, Inc.	254.0	774.7	0.3
CTSO CytoSor	bents Corporation	218.4	251.6	1.2
PTCT PTC Th	erapeutics, Inc.	205.1	1,739.6	1.7
ESPR Esperio	n Therapeutics, Inc.	194.3	823.0	0.0
TTPH Tetraph	ase Pharmaceuticals, Inc.	193.7	1,217.4	2.3
ISR IsoRay,	Inc.	192.0	80.1	1.0
ANIP ANI Pha	armaceuticals Inc	180.8	638.9	17.4
CMRXChimeri	x, Inc.	166.4	1,468.5	1.2
CBMGCellular	Biomedicine Group, Inc.	153.1	128.4	0.1
HRT Arrhythr	nia Research Technology, Inc.	142.9	21.2	6.0
NBIX Neurocr	ine Biosciences, Inc.	139.2	1,698.0	0.0




Continued Positive Analyst Coverage and Investor Outreach



Working to Save Lives Through Blood Purification



Increased Media Coverage



Operating and Financial Highlights




2014 Comparative Revenue Results

	2014	2013	% Incr.
Product revenue	\$ 3,135,387	\$ 821,787	282%
Grant and other income	987,438	1,600,880	(38)%
Total revenue	\$ 4,122,825	\$ 2,422,667	70%

- Achieved record CytoSorb® annual sales of \$3.1 M, a 282% increase over \$822K in 2013.
- Grant and other income declined by 38% as a result of the conclusion of several significant grants.
- Gross margin on product sales in 2014 were approximately 63%, as compared to 61% for 2013.




Rapidly-Growing Year-Over-Year Product Sales






Quarterly Product Sales



- Q4 2014 Product Revenue were \$871K, an increase of \$557K or 177% over Q4 2013 product revenues of \$314K.
- Q4 2014 product revenues were approximately \$161K lower than Q3 2014 revenues. Q3 2014 was the first quarter where distributor sales exceeded direct sales, and due to the bulk nature of distributor orders, sales can fluctuate from quarter to quarter.



Product Sales Trends Remain Strong





Balance Sheet and Cap Table

Consolidated Balance Sheet Data:	12	12/31/2014		
Cash and Short-Term Investments	\$	5,549,827		
Total Assets	\$	8,468,625		
Total Debt	\$	-		
Total Shareholder's Equity	\$	3,963,183		

CytoSorbents Cap Table (Pro-Forma as of 3/31/2015)							
Common stock outstanding Options	24,637,822 2,192,171	**					
Warrants Fully-diluted Common shares	2,192,171 1,517,346 28,347,339						

**Includes 1,250,000 shares issued in connection with the January 2015 \$10.3 financing.



Outlook for 2015



\$20 Billion Opportunity in Critical Care

Millions of people are admitted to the intensive care unit in hospitals in the U.S. and the European Union each year with deadly inflammatory conditions



- In these conditions, massive inflammation driven by a "cytokine storm" causes cell death and organ failure. Nearly half of all deaths in the ICU is due to organ failure with <u>no effective therapies</u>
- Because of the lack of effective therapies, approximately 1 in every 3 patients dies
- The costs can be staggering: Lack of "active" therapies lead to patients lingering days to weeks in the ICU at \$2,000-3,000 per day in the ICU* on average
- Not surprising that we spend nearly 1% of our GDP on critical care**





CytoSorb® Removes the Fuel to the Fire

- CytoSorb[®] represents a powerful immunotherapy to control inflammation
- Approved in the European Union as the only specifically approved cytokine filter
- Clinically proven to remove key cytokines in the blood of critically-ill patients
- Approved for use in any situation where cytokines are elevated
- Safe: ~5,500 human treatments, safe and well-tolerated





Goal: To Prevent or Treat Organ Failure

Improve Patient Outcome and Survival



Decrease Costs Of ICU and Patient Care



The Potential to Revolutionize Critical Care Medicine



CytoSorbents Has Tremendous Potential

CytoSorb[®] may help revolutionize critical care medicine, saving lives, and reducing costs

- Massive untapped \$20 billion unmet, medical need in critical care
- CytoSorb® sales are generating significant growth with attractive 65% gross margins
- Continued geographic expansion throughout the world
- FDA approval to start U.S. cardiac surgery pilot study the first phase to seek U.S. approval with CytoSorb®
- Expansion of existing strategic partnerships and potential new ones
- NASDAQ Capital Market up-listing and clean cap structure dramatically changes profile of company and ability for institutional and retail investors to invest



Near Term Challenges



Sales Infrastructure Targets For 2014

2013		Targets for 2014			
Direct Sales	Distributors	Partners	Direct Sales	Distributors	Partners
Germany Austria Switzerland	5 Distributors (UK, Ireland, Netherlands, Turkey, Russia)	Biocon (India)	Germany Austria Switzerland	10+ Distributors	2+ Partners
4 sales reps		10 sales reps	Distributor/Partner Support Rep		
Clinical Support (1)			Clinical Support Staff (2)		
US Manufacturing + QA/QC Staff		Support increases in sales with increases in US Manufacturing + QA/QC Staff			
Reimbursement		Reimbursement Support			



Restructuring Targets For 2015

Q1 2015		Targets for 2015				
Direct Sales	Distributors	Partners	Dire	ect Sales	Distributors	Partners
Germany Austria Switzerland	8 Distributors	Biocon Fresenius Global Cardiac Surgery Co.	_ А	ermany Nustria itzerland	12 or more Distributors total	5 or more Partners total
4 sales reps	International Sales Director + Export Business Manager		10 s	sales reps	International Sales Director + Export Business Manager	
Clinical and Product Support (2) Medical Director, Head of Scientific Marketing (2)		Clinical and Product Support (2) Medical Director, Head of Scientific Marketing (2)				
US Manufacturing + QA/QC Staff			US Manufacturing + QA/QC Staff			
Reimbursement Support				Reimbursement Support		



Q1 2015 Revenue Guidance

- In general, our product sales are too dependent on the timing and size of orders and cannot yet be accurately predicted
- We have given guidance, however, when data from the full quarter is known
- Expect that Q1 2015 CytoSorb product revenue will be in the range of \$700,000 - \$725,000 (unaudited). Adjusting for the impact in the change of the Euro, which has dropped 22% from a year ago, this is equivalent to an adjusted range of \$800,000 - \$850,000




Q&A Session

CytoSorbents Corporation

NASDAQ CM: CTSO

Phillip P. Chan, MD, PhD - CEO 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 <u>pchan@cytosorbents.com</u>



An Emerging Leader in Critical Care Immunotherapy

